Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer By Ogkologos - April 8, 2025 123 0 Facebook Twitter Google+ Pinterest WhatsApp Final survival results from the PENELOPE-B study Source RELATED ARTICLESMORE FROM AUTHOR Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer EMA Recommends Extension of Indications for Cabozantinib MOST POPULAR How International Collaboration Has Helped Improve Cancer Care in Nepal April 8, 2021 Coronavirus reports: “As a Black man with advanced prostate cancer, who... June 26, 2020 Neoadjuvant Nivolumab Plus Chemotherapy Results in Significantly Longer Event-Free Survival in... May 3, 2022 Higher Rates of Metastasis-Free Survival in Men with High-Risk Non-Metastatic Prostate... January 11, 2022 Load more HOT NEWS Քաղցկեղն իմ համայնքում՝ Քաղցկեղով երեխաների բուժումը Հայաստանում Immunotherapy Drug with Two Targets Shows Promise against HPV-Related Cancers Survivors of Childhood Cancer are at Excess Risk of Late Mortality... Online Retailer Chastised for Claiming Their Bra Reduces Risk of Breast...
